Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
- 14 September 2021
- journal article
- editorial
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 364-367
- https://doi.org/10.1016/j.clcc.2021.09.002
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trialsAnnals of Oncology, 2017
- Impact of KRAS , BRAF , PIK3CA , TP5 3 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastasesInternational Journal of Cancer, 2016
- Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2016
- BRAF in metastatic colorectal cancer: the future starts nowPharmacogenomics, 2015
- BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionBritish Journal of Cancer, 2015
- BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta‐analysisColorectal Disease, 2013
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastasesCancer, 2013
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Infarct-like NecrosisThe American Journal of Surgical Pathology, 2012
- KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS TrialJournal of Clinical Oncology, 2009